Page 1 of 1: rituximab

drlouis · Credits: 5374 My Scrapbook

rituximab is currently found to be useful in therapy for
a)RA
B)SLE
C)NHL
D)SPONDYLOARTHROPATHY
E)REACTIVE ARTHRITIS

guest · Credits: 78204 My Scrapbook My Reading List 262569 Books

I could find just in a, b, and c

drlouis · Credits: 5374 My Scrapbook

ABATACEPT (RITUXIMAB) IS the one that is currently studied in RA pts and has shown to be useful in those pts who are non-responsive or intolerant of TNF alpha inhibitors.

its called B-CELL DEPLETION THERAPY.

drkbravva · Credits: 24016 My Scrapbook My Reading List 1 Books

Only RxPG members can see links here! Register or Sign In!

Rituximab (ri-TUX-i-mab) is a monoclonal antibody. It is used to treat a type of cancer called non-Hodgkin's lymphoma.

Rituximab is to be administered only by or under the immediate supervision of your doctor. It is available in the following dosage form:

Parenteral
Injection (U.S.)

Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, rituximab is used in certain patients with the following medical conditions:

Chronic lymphocytic leukemia (a type of cancer of the blood and lymph system)
Waldenstrom's macroglobulinemia (a certain type of cancer of the blood)
Immune or idiopathic thrombocytopenic purpura (ITP) (a blood disease)
Other than the above information, there is no additional information relating to proper use, precautions, or side effects for these uses.

INDICATIONS AND USAGE
RITUXAN® (Rituximab) is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma.

The RITUXAN (Rituximab) antibody is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy- chain variable region sequences and human constant region sequences.

WARNINGS

Fatal Infusion Reactions: Deaths within 24 hours of RITUXAN infusion have been reported. These fatal reactions followed an infusion reaction complex which included hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrilation orcardiogenic shock. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. (See WARNINGS and ADVERSE REACTIONS.)

Patients who develop severe infusion reactions should have RITUXAN infusion discontinued and receive medical treatment.

Tumor Lysis Syndrome (TLS): Acute renal failure requiring dialysis with instances of fatal outcome has been reported in the setting of TLS following treatment with RITUXAN. (See WARNINGS.)

Severe Mucocutaneous Reactions: Severe mucocutaneous reactions, some with fatal outcome, have been reported in association with RITUXAN treatment. (See WARNINGS and ADVERSE REACTIONS.)

		Sign In New User? Sign Up Sign in to access your control panel and messenger!
				TechZone \| SpiderNevi \| HowTo? \| Scrapbook!